108 related articles for article (PubMed ID: 15468604)
1. Technology evaluation: ABT-510, Abbott.
Westphal JR
Curr Opin Mol Ther; 2004 Aug; 6(4):451-7. PubMed ID: 15468604
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: bevacizumab, Genentech/Roche.
Salgaller ML
Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
Hoekstra R; de Vos FY; Eskens FA; de Vries EG; Uges DR; Knight R; Carr RA; Humerickhouse R; Verweij J; Gietema JA
Eur J Cancer; 2006 Mar; 42(4):467-72. PubMed ID: 16406507
[TBL] [Abstract][Full Text] [Related]
7. Targeting the unmet medical need: the Abbott Laboratories oncology approach.
Carlson DM; Steinberg JL; Gordon G
Clin Adv Hematol Oncol; 2005 Sep; 3(9):703-10. PubMed ID: 16224444
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma.
Markovic SN; Suman VJ; Rao RA; Ingle JN; Kaur JS; Erickson LA; Pitot HC; Croghan GA; McWilliams RR; Merchan J; Kottschade LA; Nevala WK; Uhl CB; Allred J; Creagan ET
Am J Clin Oncol; 2007 Jun; 30(3):303-9. PubMed ID: 17551310
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
Ebbinghaus S; Hussain M; Tannir N; Gordon M; Desai AA; Knight RA; Humerickhouse RA; Qian J; Gordon GB; Figlin R
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6689-95. PubMed ID: 18006769
[TBL] [Abstract][Full Text] [Related]
10. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
J Clin Oncol; 2008 Dec; 26(34):5583-8. PubMed ID: 18981463
[TBL] [Abstract][Full Text] [Related]
11. Metronomic chemotherapy: teaching old drugs new tricks?
Vogelzang N
Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217
[No Abstract] [Full Text] [Related]
12. Technology evaluation: GEM-231, Hybridon.
Yeung PK
Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
[TBL] [Abstract][Full Text] [Related]
13. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
[TBL] [Abstract][Full Text] [Related]
14. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri TK
Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
[TBL] [Abstract][Full Text] [Related]
15. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
Hoekstra R; de Vos FY; Eskens FA; Gietema JA; van der Gaast A; Groen HJ; Knight RA; Carr RA; Humerickhouse RA; Verweij J; de Vries EG
J Clin Oncol; 2005 Aug; 23(22):5188-97. PubMed ID: 16051960
[TBL] [Abstract][Full Text] [Related]
16. Technology evaluation: PK1, Pfizer/Cancer Research UK.
Bilim V
Curr Opin Mol Ther; 2003 Jun; 5(3):326-30. PubMed ID: 12870445
[TBL] [Abstract][Full Text] [Related]
17. Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Kelland L
Curr Opin Mol Ther; 2007 Feb; 9(1):86-91. PubMed ID: 17330406
[TBL] [Abstract][Full Text] [Related]
18. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Kell J
Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer.
Gordon MS; Mendelson D; Carr R; Knight RA; Humerickhouse RA; Iannone M; Stopeck AT
Cancer; 2008 Dec; 113(12):3420-9. PubMed ID: 18932258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
